|
-
|
|
|
|
|
BREAKING NEWS - President Bill Clinton to Deliver Keynote Address at CRT 2012!
January 13, 2012 - President Bill Clinton, Founder of the William J. Clinton Foundation and 42nd President of the United States, will deliver the keynote address at CRT 2012.
CRT 2012 is honored to present An Evening with President Clinton: Embracing our Common Humanity.
For more, click here
|
|
|
-
|
|
|
|
|
Statins Bridge the Gender Gap
A meta-analysis of 18 clinical trials, including 141,235 patients, has shown that statins are equally effective in men and women in reducing cardiovascular outcomes and all-cause mortality.
For more, click here
|
|
|
-
|
|
|
|
|
ASCERT Provides Controversial Data
Data from the ASCERT study, presented at the STS annual meeting, has found that CABG provides better 4-year survival odds than PCI in high-risk, stable patients. Although this has broadened the smiles on many surgeons, interventional cardiologists have suggested that the study was never intended as a comparative study but a descriptive analysis of outcomes in patients undergoing PCI or CABG.
|
|
|
-
|
|
|
|
|
Strut Coverage & Remodelling Remain Key Players in Late Stent Thrombosis
OCT and IVUS examination of patients presenting with late stent thrombosis (LST) has identified lack of stent strut coverage and the remodelling index as independent predictors of LST.
For more, click here
|
|
|
-
|
|
|
|
|
Novel Biomarkers of Cardiovascular Stress in Patients with Stable Angina
Three novel biomarkers, pro-atrial natriuretic peptide (MR-proANP), midregional pro-adrenomedullin (MR-proADM), and C-terminal pro-endothelin-1 (CT-proET-1), have been identified to provide prognostic information regarding mortality and the development of heart failure in patients with stable angina.
For more, click here
|
|
|
-
|
|
|
|
|
Cangrelor – The New Kid on the Block
Cangrelor, an intravenous reversible P2Y12 receptor inhibitor, has been identified as an effective bridge therapy in patients on thienopyridines requiring CABG.
For more, click here
|
|
|
-
|
|
|
|
|
Evidence for Transradial PCI Continues to Rise
A comparison of radial versus femoral-based PCI in patients presenting with STEMI from the Italian multicenter REAL registry has demonstrated a decreased 2-year mortality rate and a reduction in the need for vascular surgery and/or surgery with the former.
For more, click here
|
|
|
-
|
|
|
|
|
Recommendation Made to Halt FAME II Enrollment
Based on a positive interim analysis showing a significant reduction in the need for hospital readmission and urgent revascularization when FFR-guided assessment was used to direct treatment in patients with CAD, the independent Data Safety Monitoring Board (DSMB) of the FAME II trial has recommended investigators stop patient enrollment as the DSMB considers it unethical to continue to randomize patients to optimal medical therapy alone.
For more, click here
|
|
|
-
|
|
|
|
|
Aspirin Not Indicated in Primary Prevention
The latest meta-analysis, involving more than 100,000 patients, has revealed that in the context of primary prevention aspirin is associated with greater harm than benefit and should not be prescribed.
For more, click here
|
|
|
-
|
|
|
|
|
TAVI in Lower Risk Patients – Is it the Right Time?
An analysis of 420 patients divided into quartiles of risk has concluded that, as compared to higher surgical risk patients, better clinical outcomes can be expected.
For more, click here
|
|
|
-
|
|
|
|
|
SCAAR Confirms the Safety & Efficacy of New-Generation DES
The Swedish Coronary Angiography & Angioplasty Registry has demonstrated that the use of new-generation DES is associated with reductions in restenosis rates (38%), stent thrombosis (43%), and death (23%).
For more, click here
|
|
|
-
|
|
|
|
|
Vascular Complications Dramatically Reduced with Rigorous Pt. Selection in PAVR
In patients undergoing PAVR, vascular complications have been shown to occur more frequently in those with arterial calcification, peripheral arterial disease, and when the arterial diameter is smaller than the external sheath diameter.
For more, click here
|
|
|
-
|
|
|
|
|
EVEREST II Provides Reassuring Acute & 12-month Results
The use of the MitraClip device in patients with severe MR who are at high risk for surgery has been shown to lead to significant reductions in MR, as well as improvements in clinical outcomes and reverse left ventricular remodelling.
For more, click here
|
|
|
-
|
|
|
|
|
Bariatric Surgery Reduces Mortality & Cardiovascular Events
The Swedish Obese Subjects (SOS) study has shown that as compared to medical therapy, bariatric surgery in obese subjects is associated with reductions in cardiovascular death, and cardiovascular events (MI or stroke).
For more, click here
|
|
|
|
















|
 |
 1/9/2012 |
Strengths, Limitations, and the "Raison d’Être" for Appropriateness Criteria? Manesh R. Patel, MD |  1/4/2012 |
Clinical Implications of Electrocardiographic Left Ventricular Strain and Hypertrophy in Asymptomatic Aortic Stenosis: The SEAS study Anders M. Greve, MD, et al. |  11/23/2011 |
Safety and Efficacy of a Pharmaco-invasive Reperfusion Strategy in Rural ST-elevation Myocardial Infarction Patients with Expected Delays to Long-distance Transfers David M. Larson, MD, et al. |  11/23/2011 |
Operator Experience and Carotid Stenting Outcomes in Medicare Beneficiaries B.K. Nallamothu, MD, MPH |  11/16/2011 |
PCI vs. Bypass Surgery: The European View: State of the Art Sigmund Silber, MD |  11/9/2011 |
Safety and Efficacy of Resolute ZES in Elderly Patients: Outcomes at 12 Months from the Global RESOLUTE Clinical Program Ganesh Manoharan, MD, et al. |  11/9/2011 |
Five-Year Clinical Outcomes from the RESOLUTE First-In-Man Trial Ian T. Meredith, et al. |
|
 |
 |
|
|
 |

 |
|
Updated January 30, 2012
Click on the headline below to go directly to the abstract! |
Results from SPARC (Study of Myocardial Perfusion and Coronary Anatomy Imaging Roles in Coronary Artery Disease).
R Hachamovitch, B Nutter, et al.
JACC 2012; 59:462-474 |
Chronic Hyperglycemia and Subclinical Myocardial Injury.
J Rubin, K Matsushita, et al.
JACC 2012; 59:484-489 |
Lifetime Risks of Cardiovascular Disease.
JD Berry, A Dyer, et al.
NEJM 2012; 366:321-329 |
The Efficacy of Xience/Promus vs. Cypher to Reduce Late Loss after Stenting (EXCELLENT) Randomized, Multicenter Study.
H-C Gwon, J-Y Hahn, et al.
Circulation 2012; 125:505-513 |
Short-Term Outcomes of AMI in Patients with Acute Kidney Injury. A Report from the National Cardiovascular Data Registry.
C Fox, P Muntner, et al.
Circ 2012; 125:497-504 |
Comparison of Incidence of Bleeding and Mortality of Men vs. Women with STEMI Treated with Fibrinolysis.
R Mehta, A Stebbins, et al.
AJC 2012; 109:320-326 |
Self-monitoring of Oral Anticoagulation: Systematic Review and Meta-analysis of Individual Patient Data.
C Heneghan, A Ward, et al.
Lancet 2012; 379:322-334 |
Eight Genetic Loci Associated with Variation in Lipoprotein-associated Phospholipase A2 Mass and Activity and Coronary Heart Disease: Meta-analysis of Genome-wide Association Studies from Five Community-based Studies.
H Grallert, J Dupuis, et al.
EHJ 2012; 33:238-251 |
|
 |
|
 |
Safety and Efficacy of a Pharmaco-invasive Reperfusion Strategy in Rural ST-elevation Myocardial Infarction Patients with Expected Delays to Long-distance Transfers
David M. Larson, MD, et al. |
PCI vs. Bypass Surgery: The European View: State of the Art
Sigmund Silber, MD, et al. |
Safety and Efficacy of Resolute ZES in Elderly Patients: Outcomes at 12 Months from the Global RESOLUTE Clinical Program
Ganesh Manoharan, MD, et al. |
Operator Experience and Carotid Stenting Outcomes in Medicare Beneficiaries
BK Nallamothu, MD, et al. |
Late-Term Clinical Results from the ENDEAVOR Program: 5-Year Follow up
David E. Kandzari, MD, et al. |
Five-Year Clinical Outcomes from the RESOLUTE First-In-Man Trial
Ian T. Meredith, MD, et al. |
The Resolute Zotarolimus-eluting Stent in Patients with Diabetes Mellitus: One Year Outcomes
Sigmund Silber, MD |
ISAR-REACT 4 Trial
Adnan Kastrati, MD et al. |
ELEVATE Trial
JL Mega, MD, et al. |
PARIS Study
Roxana Mehran, MD |
|
|
 |
Atherosclerosis and HDL Therapy
Course Will Focus on New Modalities
Renu Virmani, MD |
Complex Coronary Interventions
Two-Day Course Gives
Cardiologists Hands-On Solutions
Lowell Satler, MD |
New Session Offers an In-Depth Look at Clinical Research
Alexandra J. Lansky, MD |
New Approaches Are an Integral
Part of this Year's CTO Forum
Craig A. Thompson, MD |
Endovascular Track: A Little of This,
More of That, Something for Everyone
Mark H. Wholey, MD |
New Technologies, Structural Heart Among Topics at Nurse & Tech Symposium
Julie Logan, RN |
Stroke Management Course to Look at Treatment Options, Comparitive Outcomes
William Gray, MD |
| There's an App for That: How
Telemedicine Helps Cardiologists |
CRT 2012: An Overview
Ron Waksman, MD |
2012: The Year of the Valve
|
|
|

|